EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma

Yu-Fan Huang, Jia-Jing Qin, Xiao-Qin Wu, Hui Liu, Susu Luo, Zhe-Qi Xu

Expert Review of Pharmacoeconomics & Outcomes Research · 17.08.2026 · 1-8

DOI: 10.1080/14737167.2026.2719622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 17.08.2026. Verfasst von Yu-Fan Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Postdoctoral Fellowship Program of CPSF, National Natural Science Foundation of China, Soaring Talent Development Program of Eastern Hepatobiliary Surgery Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Cost-effectivenessanlotinibpartitioned survival modelpenpulimabunresectable hepatocellular carcinoma

Autor:innen und Institutionen

  • Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
  • The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.

Förderung

  • Postdoctoral Fellowship Program of CPSF
  • National Natural Science Foundation of China
  • Soaring Talent Development Program of Eastern Hepatobiliary Surgery Hospital
  • Natural Science Foundation of Fujian Province
  • University-level Basic Medical Research Project of Naval Medical University

Zitieren

APA

Huang, Y. F., Qin, J. J., Wu, X. Q., Liu, H., Luo, S., & Xu, Z. Q. (2026). Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research, 1-8. https://doi.org/10.1080/14737167.2026.2719622

Vancouver

Huang YF, Qin JJ, Wu XQ, Liu H, Luo S, Xu ZQ. Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-8. doi:10.1080/14737167.2026.2719622

BibTeX
@article{Huang2026,
  author = {Huang, Yu-Fan and Qin, Jia-Jing and Wu, Xiao-Qin and Liu, Hui and Luo, Susu and Xu, Zhe-Qi},
  title = {Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  pages = {1--8},
  doi = {10.1080/14737167.2026.2719622}
}
Kostenlos starten →